Myocardial infarction calcium channel blockers adversely

Retrospective case-control studies reported that immediate-acting nifedipine increased the risk of myocardial infarction in patients with hypertension. Slow-release and long-acting vasoselective calcium channel blockers are usually well tolerated. Flowever, dihydropyridines, compared with angiotensin-converting enzyme (ACE) inhibitors, have been reported to increase the risk of adverse cardiac events in... 

In patients with unstable angina, immediate-release short-acting calcium channel blockers can increase the risk of adverse cardiac events and therefore are contraindicated (see Toxicity, above). However, in patients with non-Q-wave myocardial infarction, diltiazem can decrease the frequency of postinfarction angina and may be used. 

There has been some concern that the shorter-acting calcium channel blockers may adversely affect the risk of myocardial infarction and cardiac death. The evidence is based on case-control studies which cannot escape the possibility that sicker patients, i.e. with worse hypertension or angina, received calcium charmel blockade. The safety and efficacy of the class has been strengthened by the recent findings of two prospective comparisons with other antihypertensives. ... 

The possibility that calcium channel blockers can cause cardiovascular adverse effects in pregnancy has been widely debated (SED-14, 598) (SEDA-20, 185) (SEDA-21, 208) (SEDA-22, 214). An uncomplicated non-Q wave myocardial infarction has been reported during nifedipine therapy for preterm labor (43). 

---